$1.16
0.87%
Nasdaq, Mon, Oct 19 2026.
ISIN
US55279B2025
Symbol
MEIP

MEI Pharma, Inc. Stock price

$1.16
-0.12 9.38% 1M
-0.03 2.52% 6M
-0.16 12.12% YTD
-0.82 41.41% 1Y
-4.21 78.39% 3Y
-43.27 97.39% 5Y
-24.01 95.39% 10Y
-2,907.13 99.96% 20Y
Nasdaq, Closing price Mon, Oct 19 2026
+0.01 0.87%
ISIN
US55279B2025
Symbol
MEIP
Industry

Is MEI Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
- | -
P/B
-
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
- | -
Increased
0 Years
Financials
Revenue | estimate
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
- | -100.0%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
Financial Health
Equity Ratio
79.8%
Return on Equity
53.8%
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
-
FCF per Share
-
Short interest
8.3%
Employees
28
Rev per Employee
$2.3m

MEI Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a MEI Pharma, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a MEI Pharma, Inc. forecast:

Hold
50%
Sell
50%

Financial data from MEI Pharma, Inc.

Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
49% 49%
-
- Research and Development Expense 7.78 7.78
49% 49%
-
-33 -33
245% 245%
-
- Depreciation and Amortization 0.49 0.49
36% 36%
-
EBIT (Operating Income) EBIT -34 -34
250% 250%
-
Net Profit -32 -32
221% 221%
-

In millions USD.

Don't miss a Thing! We will send you all news about MEI Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Head office United States
CEO Mr. File
Employees 28
Founded 2000
Website www.meipharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today